Tobam Takes $749,000 Position in Abbott Laboratories $ABT

by · The Markets Daily

Tobam acquired a new position in Abbott Laboratories (NYSE:ABT – Free Report) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 5,981 shares of the healthcare product maker’s stock, valued at approximately $749,000.

A number of other institutional investors have also recently bought and sold shares of ABT. Arwa LLC purchased a new position in Abbott Laboratories during the 4th quarter valued at about $1,284,000. Groupama Asset Managment lifted its position in shares of Abbott Laboratories by 8.1% in the fourth quarter. Groupama Asset Managment now owns 64,122 shares of the healthcare product maker’s stock worth $8,034,000 after purchasing an additional 4,784 shares in the last quarter. TD Capital Management LLC boosted its holdings in shares of Abbott Laboratories by 35.7% during the fourth quarter. TD Capital Management LLC now owns 733 shares of the healthcare product maker’s stock worth $92,000 after purchasing an additional 193 shares during the period. Sit Investment Associates Inc. boosted its stake in shares of Abbott Laboratories by 3.9% during the 4th quarter. Sit Investment Associates Inc. now owns 151,063 shares of the healthcare product maker’s stock valued at $18,927,000 after buying an additional 5,685 shares during the period. Finally, Tempo Wealth LLC acquired a new stake in Abbott Laboratories during the fourth quarter valued at $311,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

Shares of ABT opened at $88.48 on Friday. The company has a market capitalization of $154.12 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06. The company’s fifty day moving average price is $90.08 and its 200 day moving average price is $106.60.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ABT shares. JPMorgan Chase & Co. reduced their price objective on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Benchmark reduced their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Daiwa Securities Group downgraded Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a research note on Wednesday, April 22nd. The Goldman Sachs Group lowered their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Finally, Bank of America reduced their target price on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.30.

Get Our Latest Stock Report on Abbott Laboratories

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.46% of the company’s stock.

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Articles

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).